SAN FRANCISCO — A large Phase 3 trial of the investigational Alzheimer’s drug lecanemab found that treatment slowed decline on a combined cognitive and functional measure by 27% over 18 months compared with placebo, giving the anti-amyloid approach one of its clearest late-stage clinical tests to date. Full results from the 1,795-patient Clarity AD study were published this week in the New England Journal of Medicine and presented at the Clinical Trials on Alzheimer’s Disease conference.

The result is statistically persuasive but clinically more complicated. Patients receiving lecanemab still worsened over the 18-month trial; the treatment reduced the rate of decline rather than stopping or reversing disease. It also produced important safety signals, including amyloid-related imaging abnormalities and infusion reactions, that physicians and regulators will have to weigh against the measured benefit.

A modest but consistent treatment effect

Clarity AD enrolled 1,795 people with early Alzheimer’s disease — mild cognitive impairment or mild dementia with evidence of amyloid pathology — and randomly assigned 898 to lecanemab and 897 to placebo. According to the sponsor’s full-results release, the mean change from baseline on the Clinical Dementia Rating–Sum of Boxes, or CDR-SB, was 1.21 points with lecanemab and 1.66 with placebo. The adjusted difference was minus 0.45 points, corresponding to a 27% reduction in decline on that measure.

Secondary endpoints moved in the same direction. Eisai and Biogen reported treatment differences favoring lecanemab on measures including amyloid burden, the ADAS-Cog14 cognitive scale, the Alzheimer’s Disease Composite Score and a measure of activities of daily living. The companies had disclosed the positive topline result in September, reporting that the study met its primary endpoint and all key secondary endpoints.

The consistency matters because Alzheimer’s trials have repeatedly produced promising biological effects without clear improvements in cognition or daily function. Lecanemab is designed to bind soluble amyloid-beta aggregates and promote their removal. An earlier randomized Phase 2b study had provided evidence of amyloid reduction and potential slowing of clinical decline, but its statistical design and dose interruptions left important questions for a larger confirmatory trial.

Safety will shape the benefit-risk debate

The Phase 3 results also define the treatment’s liabilities. Amyloid-related imaging abnormalities involving edema or effusion, known as ARIA-E, occurred in 12.6% of patients receiving lecanemab and 1.7% receiving placebo. Symptomatic ARIA-E was less common, but the imaging finding is clinically significant because anti-amyloid antibodies can also be associated with microhemorrhages and other bleeding-related abnormalities. Infusion-related reactions occurred in 26.4% of the lecanemab group.

Serious adverse events were reported in 14.0% of patients receiving lecanemab and 11.3% receiving placebo. Those figures do not establish that every event was caused by treatment, but they reinforce that widespread use would require MRI surveillance, careful patient selection and protocols for managing imaging abnormalities and infusion reactions.

The drug is not being studied as a general dementia therapy. The Clarity AD trial design focused on people at an early disease stage with confirmed amyloid pathology, reflecting the biological rationale that removing amyloid may have greater value before extensive neurodegeneration has accumulated. That limits how broadly the findings can be applied to patients with later-stage Alzheimer’s disease.

Regulatory review is already underway

The Food and Drug Administration accepted Eisai’s biologics license application for lecanemab in July and granted priority review under the accelerated-approval pathway. The agency set a Prescription Drug User Fee Act action date of Jan. 6, 2023. That application is based on lecanemab’s effect on amyloid, a surrogate endpoint, while Clarity AD is intended to provide confirmatory evidence of clinical benefit.

FDA had earlier granted lecanemab Breakthrough Therapy designation, another indication that the agency viewed the program as potentially addressing a serious condition with unmet need. The new Phase 3 data now give regulators a much fuller benefit-risk record than was available from biomarker change alone.

The distinction between statistical and practical significance is likely to be central. A 0.45-point difference on an 18-point CDR-SB scale is measurable and consistent across a large trial, but patients, families and clinicians will have to decide how much that slower deterioration is worth relative to intravenous infusions, monitoring, imaging risk and cost. The trial does not show recovery of lost memory or independence.

A consequential test of the amyloid hypothesis

Lecanemab’s result arrives after years of controversy over whether clearing amyloid plaques translates into clinically meaningful benefit. The antibody targets protofibrils and other soluble aggregated forms of amyloid beta, a somewhat different biological emphasis from some earlier agents. The trial’s amyloid PET findings confirm a substantial effect on the target, while the clinical endpoints provide evidence that the biological change is accompanied by slower decline.

That does not settle every scientific question about Alzheimer’s disease. Tau pathology, neuroinflammation, vascular injury and other mechanisms remain important, and the disease is heterogeneous. Nor does one positive antibody trial establish that all amyloid-targeting approaches will work. What Clarity AD does provide is a large randomized dataset in which amyloid removal and a statistically significant slowing of cognitive and functional deterioration appear together.

For patients with early Alzheimer’s disease, the finding is therefore both encouraging and bounded. Lecanemab may offer additional time before decline progresses to the same degree seen with placebo, but it is not a cure and it brings medical risk. The next decisions — from FDA, physicians, health systems and eventually payers — will determine whether that tradeoff becomes part of routine Alzheimer’s care.